AQP4 and optic neuritis: In the present study, we investigated the usage status of three biologic agents in Japan: satralizumab, eculizumab and inebilizumab, in patients with AQP4-Ab positive NMOSD, focusing on those with newly diagnosed or relapsed optic neuritis.